Immunophenotyping at the Time of Diagnosis Distinguishes Two Groups of Nasopharyngeal Carcinoma Patients: Implications for Adoptive Immuno-therapy

International Journal of Biological Sciences

Volumn 7, Issue 5, 2011, Pages 607-617

  Li, Jiang ^a   Chen, Qiu yan ^a   Mo, Haoyuan ^a   Zhang, Yi lan ^a   Huang, Zhou feng ^a   Zeng, Yi xin ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

EBV specific CTL; Immunophenotype; Immunotherapy; LMP1; NPC

Indexed keywords

HUMAN HERPESVIRUS 4;

EID: 79960143714     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.7.607     Document Type: Article

References (36)

1. Pattle SB, Farrell PJ. The role of Epstein-Barr virus in cancer. Expert Opin Biol Ther 2006; 6: 1193-1205.
2. Kanegane H, Nomura K, Miyawaki T, Tosato G. Biological aspects of Epstein-Barr virus (EBV)-infected lymphocytes in chronic active EBV infection and associated malignancies. Crit Rev Oncol Hematol 2002; 44: 239-249.
3. Knecht H, Berger C, Rothenberger S et al. The role of Ep-stein-Barr virus in neoplastic transformation. Oncology 2001; 60: 289-302.
4. Kelleher CA, Dreyfus DH, Jones JF, Gelfand EW. EBV infection of T cells: potential role in malignant transformation. Semin Cancer Biol 1996; 7: 197-207.
5. Fuse S, Molloy MJ, Usherwood EJ. Immune responses against persistent viral infections: possible avenues for immunothera-peutic interventions. Crit Rev Immunol 2008; 28: 159-183.
6. Halwani R, Doroudchi M, Yassine-Diab B et al. Generation and maintenance of human memory cells during viral infection. Springer Semin Immunopathol 2006; 28: 197-208.
7. Williams H, McAulay K, Macsween KF et al. The immune response to primary EBV infection: a role for natural killer cells. Br J Haematol 2005; 129: 266-274.
8. Khanna R, Burrows SR. Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases. Annu Rev Microbiol 2000; 54: 19-48.
9. Rooney CM, Heslop HE, Brenner MK. EBV specific CTL: a model for immune therapy. Vox Sang 1998; 74 (Suppl 2): 497-498.
10. Moss DJ, Burrows SR, Khanna R et al. Immune surveillance against Epstein-Barr virus. Semin Immunol 1992; 4: 97-104.
11. Comito MA, Sun Q, Lucas KG. Immunotherapy for Ep-stein-Barr virus-associated tumors. Leuk Lymphoma 2004; 45: 1981-1987.
12. Amrolia PJ, Muccioli-Casadei G, Yvon E et al. Selective deple-tion of donor alloreactive T cells without loss of antiviral or an-tileukemic responses. Blood 2003; 102: 2292-2299.
13. Heslop HE, Slobod KS, Pule MA et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010;115: 925-935.
14. Heslop HE. Biology and treatment of epstein-barr vi-rus-associated non-hodgkin lymphomas. Hematology Am Soc Hematol Educ Program 2005;:260-266.
15. Louis CU, Straathof K, Bollard CM et al. Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC pa-tients. Blood 2009; 113: 2442-2450.
16. Straathof KC, Bollard CM, Popat U et al. Treatment of naso-pharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes. Blood 2005; 105: 1898-1904.
17. Comoli P, Pedrazzoli P, Maccario R et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol 2005; 23: 8942-8949.
18. Chapman AL, Rickinson AB, Thomas WA et al. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy. Cancer Res 2001; 61: 6219-6226.
19. Li J, Zeng XH, Mo HY et al. Functional inactivation of EBV-specific T-lymphocytes in nasopharyngeal carcinoma: im-plications for tumor immunotherapy. PLoS ONE 2007; 2: e1122.
20. Shao JY, Li YH, Gao HY et al. Comparison of plasma Ep-stein-Barr virus (EBV) DNA levels and serum EBV immuno-globulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma. Cancer 2004; 100: 1162-1170.
21. Jimenez R, Ramirez R, Carracedo J et al. Cytometric bead array (CBA) for the measurement of cytokines in urine and plasma of patients undergoing renal rejection. Cytokine 2005; 32: 45-50.
22. Thorn RM, Palmer JC, Manson LA. A simplified 51Cr-release assay for killer cells. J Immunol Methods 1974; 4: 301-315.
23. Li J, Zhang XS, Xie D et al. Expression of immune-related mol-ecules in primary EBV positive Chinese nasopharyngeal carci-noma: associated with latent membrane protein 1 (LMP1) ex-pression. Cancer Biol Ther 2007; 6: 1997-2004.
24. Remmele W, Schicketanz KH. Immunohistochemical determi-nation of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs. subjective grading (IRS). Pathol Res Pract 1993; 189: 862-866.
25. Merlo A, Turrini R, Dolcetti R et al. Adoptive cell therapy against EBV-related malignancies: a survey of clinical results. Expert Opin Biol Ther 2008; 8: 1265-1294.
26. Brander C, Suscovich T, Lee Y et al. Impaired CTL recognition of cells latently infected with Kaposi's sarcoma-associated her-pes virus. J Immunol 2000; 165: 2077-2083.
27. Raab-Traub N. Epstein-Barr virus in the pathogenesis of NPC. Semin Cancer Biol 2002; 12: 431-441.
28. Tao Q, Young LS, Woodman CB, Murray PG. Epstein-Barr virus (EBV) and its associated human cancers--genetics, epige-netics, pathobiology and novel therapeutics. Front Biosci 2006; 11: 2672-2713.
29. Lin CL, Lo WF, Lee TH et al. Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. Cancer Res 2002; 62: 6952-6958.
30. Creighton CJ, Bromberg-White JL, Misek DE et al. Analysis of tumor-host interactions by gene expression profiling of lung adenocarcinoma xenografts identifies genes involved in tumor formation. Mol Cancer Res 2005; 3: 119-129.
31. Khong HT, Wang QJ, Rosenberg SA. Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression. J Immunother 2004; 27: 184-190.
32. Klaamas K, Kurtenkov O, Rittenhouse-Olson K et al. Expres-sion of tumor-associated Thomsen-Friedenreich antigen (T Ag) in Helicobacter pylori and modulation of T Ag specific immune response in infected individuals. Immunol Invest 2002; 31: 191-204.
33. Michel S, Linnebacher M, Alcaniz J et al. Lack of HLA class II antigen expression in microsatellite unstable colorectal carci-nomas is caused by mutations in HLA class II regulatory genes. Int J Cancer 2010;127: 889-898.
34. Poggi A, Zocchi MR. Mechanisms of tumor escape: role of tumor microenvironment in inducing apoptosis of cytolytic ef-fector cells. Arch Immunol Ther Exp (Warsz) 2006; 54: 323-333.
35. Bollard CM, Gottschalk S, Leen AM et al. Complete responses of relapsed lymphoma following genetic modification of tu-mor-antigen presenting cells and T-lymphocyte transfer. Blood 2007; 110: 2838-2845.
36. Zhang YL, Li J, Mo HY et al. Different subsets of tumor infil-trating lymphocytes correlate with NPC progression in differ-ent ways. Mol Cancer 2010;9: 4.